ClinicalTrials.gg
RecruitingNCT01670383Updated Nov 24, 2023

Repository for Sepsis and Postresuscitation Samples

An observational study in Cardiac Arrest and Sepsis, sponsored by Seoul National University Hospital. Recruiting at 1 site in Korea, Republic of. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2023-11-24.

Sponsored by Seoul National University Hospital · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Heart Arrest by Seoul National University Hospital — 4 open to participants now, 5 under way, none of them phase 3. Heart Arrest · Seoul National University Hospital.

Started
2006
the only one that year
Observational
4 of 12
1 open now
Registered
2nd of 12
by date

Among the 12 studies in Heart Arrest by Seoul National University Hospital, this one is the only one that started in 2006, is one of 4 observational ones, and was the 2nd registered.

Heart Arrest

927 studies on the registry are indexed under Heart Arrest; 227 are open to participants now.

Browse Heart Arrest studies →

Open to participants now

4 of the 12 studies in Heart Arrest by Seoul National University Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 157 Heart Arrest studies recruiting now, 109 (69%) set no upper age limit and 28 (18%) stop at 75 or younger; 30 take children under 18; 18 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Heart Arrest by Seoul National University Hospital, or all of them as a file.
02

Study summary

The objective of this study is to find a new therapeutic strategy by investigating the serial serum samples of patients with sepsis or postresuscitation state.

03

Conditions studied

  • Cardiac Arrest
  • Sepsis

Keywords

  • Cardiac Arrest
  • Sepsis
  • Biological Markers
  • Anti-Inflammation Agents
  • Antioxidants
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Sepsis patients admitted to ICU Postresuscitation patients admitted to ICU

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age over 16 years old
  • Admitted to ICU
  • Diagnosed as having sepsis or as postresuscitation status
  • Definition of sepsis: 2 or more SIRS criteria + infection is suspected
  • Definition of postresuscitation status: Survived from non-traumatic cardiac arrest

Exclusion criteria

Exclusion Criteria:

  • refusal to participate
  • DNAR status
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500 participants (estimated)
Biospecimen retention
Samples without dna

Groups and cohorts

  • Postresuscitation group

    Adults (age over 16 years old) who have survived from nontraumatic cardiac arrest and admitted to ICU.

  • Sepsis group

    Adults (age over 16 years old) who satisfy the sepsis criteria (SIRS\>=2 and infection is suspected for a cause) and admitted to the ICU.

06

What researchers measure

Primary outcomes

  1. 1-month mortality

    All cause mortality within 1-month

    Time frame: 1 month

Secondary outcomes

  1. Hospital mortality

    All cause mortality during hospitalization

    Time frame: until hospital discharge, an expected average of 2 weeks

  2. ICU length of stay

    Time frame: Until ward transfer or discharge, an expected average of 7 days

  3. Favorable neurologic outcome

    Favorable neurologic outcome is used for outcome measure in postresuscitation patients only. Favorable neurologic outcome means cerebral performance category 1 and 2. This outcome is measured at discharge and 6-month after admission.

    Time frame: at discharge, an expected average of 2 weeks and at 6-month

07

Study locations

1 of 1 sites recruiting
  • Seoul National University Hospital
    Seoul, 110-744, Korea, Republic of
    Recruiting
    • Kyung Su Kim, MD, PhD · Contact
    • Kyung Su Kim, MD, PhD · Sub investigator
    • Woon Yong Kwon, MD, PhD · Sub investigator
    • Gil Joon Suh, MD, PhD · Principal investigator
08

References and documents

Publications

  • Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001 Jul;29(7):1303-10. doi: 10.1097/00003246-200107000-00002. PubMed 11445675 ↗
  • Dombrovskiy VY, Martin AA, Sunderram J, Paz HL. Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: a trend analysis from 1993 to 2003. Crit Care Med. 2007 May;35(5):1244-50. doi: 10.1097/01.CCM.0000261890.41311.E9. PubMed 17414736 ↗
  • Cohen J. The immunopathogenesis of sepsis. Nature. 2002 Dec 19-26;420(6917):885-91. doi: 10.1038/nature01326. PubMed 12490963 ↗
  • Schneider A, Bottiger BW, Popp E. Cerebral resuscitation after cardiocirculatory arrest. Anesth Analg. 2009 Mar;108(3):971-9. doi: 10.1213/ane.0b013e318193ca99. PubMed 19224811 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2006, a primary completion of Dec 2028 and a completion of Dec 2028. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2012
First posted
Aug 22, 2012
Start
Jul 2006
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2028
Last update
Nov 24, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 24, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01670383
Responsible party
Gil Joon Suh (Professor, Seoul National University Hospital) — Principal investigator
First posted
Aug 22, 2012
Start date
Jul 2006
Primary completion
Dec 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Nov 24, 2023

Study contacts

Kyung Su Kim, MD, PhD
Contact
kanesu@gmail.com
82-10-8033-1127
Gil Joon Suh, Professor
study director · Seoul National University Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion